May 24 2012
Yesterday, May 23, the FDA Cardiovascular and Renal Drugs Advisory Committee failed to endorse the use of rivaroxaban (Xarelto, Bayer) for acute coronary syndrome. SeeTheHeart.org for details.
Comments (0)
Anticoagulant Therapy
No comments here.